LEMAITRE VASCULAR, INC. Impairment of Intangible Assets, Finite-lived
LEMAITRE VASCULAR, INC. (LMAT) reported Impairment of Intangible Assets, Finite-lived of $3.40 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-02-28
- LEMAITRE VASCULAR, INC. impairment of intangible assets, finite-lived for the quarter ending 2014-06-30 was $200.00K.
- LEMAITRE VASCULAR, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $3.40M.
- LEMAITRE VASCULAR, INC. impairment of intangible assets, finite-lived for fiscal 2019 was $4.50M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|
| 2021-12-31 | $3.40M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $4.50M 10-K · filed 2022-02-28 | |
| 2014-06-30 | $200.00K 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |